Monoclonal Antibody to Alanine Aminotransferase (ALT)
Code | Size | Price |
---|
MAA207Hu29-20ul | 20uL | £85.00 |
Quantity:
MAA207Hu29-100ul | 100ul | £158.00 |
Quantity:
MAA207Hu29-200ul | 200ul | £213.00 |
Quantity:
MAA207Hu29-1ml | 1ml | £487.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1 Kappa
Antibody Clonality: Monoclonal
Antibody Clone: E3
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GPT; ALAT; SGPT; AAT1; GPT1; Serum Glutamic Pyruvic Transaminase; Alanine Transaminase; Glutamate pyruvate transaminase 1; Glutamic--alanine transaminase 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Alanine Aminotransferase
Potency (Clone Number):
E3
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Alanine Aminotransferase (ALT) | RPA207Hu03 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||